Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19590662 | 0.84 | — | — | |
| SCHEMBL23492258 | 0.84 | JAK2 (0.32) | JAK2JAK1TYK2JAK3OPRM1 | |
| SCHEMBL19768953 | 0.82 | JAK2 (0.32) | JAK2JAK1TYK2JAK3OPRM1 | |
| SCHEMBL26989944 | 0.78 | NCF1 (0.36) | JAK2JAK1JAK3OPRM1 | |
| SCHEMBL22564911 | 0.78 | OPRM1 (0.36) | OPRM1 | |
| SCHEMBL20927236 | 0.76 | NCF1 (0.38) | — | |
| SCHEMBL24480845 | 0.76 | — | — | |
| SCHEMBL18459235 | 0.75 | ACHE (0.31) | OPRM1 | |
| SCHEMBL22564906 | 0.74 | USP2 (0.33) | OPRM1 | |
| SCHEMBL24480647 | 0.73 | CYP1A2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10351547-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2019-01-03 | — | — | US | disclosed |
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2018013676-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | SLC6A4 233/4885HRH3 823/4885JAK2 533/4885 |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | SLC6A4 233/4885HRH3 823/4885JAK2 533/4885 |
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | SLC6A4 233/4885HRH3 823/4885JAK2 533/4885 |
| US-10351547-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | SLC6A4 233/4885HRH3 823/4885JAK2 533/4885 |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | SLC6A4 233/4885HRH3 823/4885JAK2 533/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | SLC6A4 233/4885HRH3 823/4885JAK2 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.